Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic. (January 2021)

• Record Type: Journal Article
• Authors: Baay, Marc; Lina, Bruno; Fontanet, Arnaud; Marchant, Arnaud; Saville, Melanie; Sabot, Philippe; Vandeputte, Joris; Neels, Pieter
• Is Part Of: Biologicals. Volume 69(2021)
• Page Start: 76
• Page End: 82
• Publication Date: 2021-01
• Subjects: SARS-CoV-2 -- Virology -- Epidemiology -- Immunology -- Vaccine; Biological products -- Standards -- Periodicals; Biological Products -- Periodicals; Biological Products -- standards -- Periodicals; Produits biologiques -- Normes -- Périodiques; Biological products -- Standards; Periodicals; 615.37
• DOI: 10.1016/j.biologicals.2020.11.003
• Languages: English
• ISSNs: 1045-1056

Abstract

Abstract: This International Alliance for Biological Standardization COVID-19 webinar was organized to provide an update on the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2, none months after COVID-19 was declared a public health emergency of international concern. It brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries. Highlights: Recombination probably led to a virus that acquired human-to-human transmissibility. Initially, SARS-CoV-2 infection in the second wave was mistakenly interpreted as more benign. Neutralizing antibodies likely contribute to control of SARS-CoV-2 disease. A mucosal immune response (IgA in nasal mucus or saliva) may be a useful correlate of protection. COVAX aims to deliver 2 billion doses of vaccine by the end of 2021, to all the countries around the world.